🇨🇭·10h agoIndustry
FDA grants Priority Review to Roche’s Enspryng, the first and only at-home subcutaneous treatment option for thyroid eye disease (TED)
Publisher
R
Roche Newsroom
Switzerland
This page provides a limited summary and publisher metadata to support discovery before sending readers to the original article.
Read originalAt a glance
- Publisher
- Roche Newsroom
- Region
- Switzerland
- Scope
- Industry
- Published
- June 30, 2026
In-platform summary, original article off-platform
This page presents the title, publisher metadata, and a limited summary excerpt to help users judge relevance first. Full-text reading stays on the publisher's original site.
Source route
Continue on roche.com
Leave the platform to read the original full article on the publisher site.
Source: Roche Newsroom
Scope: Industry
Related coverage
More related coverage
Chugai Pharmaceutical News/7h ago
エンスプリングに関するロシュ社の発表について（甲状腺眼症に対する申請が米国FDAに受理）
Chugai Pharmaceutical/7h ago
Roche’s Announcement Regarding Enspryng (FDA Accepts Application for Thyroid Eye Disease)
Chugai Pharmaceutical News/8h ago
治験候補患者抽出の精度向上・効率化に向け、リアルワールドデータと生成AI（LLM）を用いた共同研究を開始
Chugai Pharmaceutical/8h ago